Born in Novara in 1978, AMNOL Chimica Biologica has been present on the pharmaceutical market with an approach of continuous innovation ever since.
At its onset, AMNOL began to implement training activities and research of staff coming from biochemistry, biotechnology and pharmaceutical industries; over the years its target has expanded to the scientific research and development activities, thus becoming the major activity of the company.
A constant growth over the years with an innovative and forward-looking approach to business.
During the first two decades of AMNOL's existence, the company has also been involved in research and development of biotechnological products and carried out numerous patents having biochemical, biotechnological and nanotechnological matrices, in partnership with some of the most important European pharmaceutical companies.
In 1998 AMNOL made a turning point: a new team of managers concentrated the company’s activities on the production and marketing of nutritional health supplements and dermocosmetics based on biological extracts, both in Italy and abroad.
The innovative approach has had a strong interest in the national and international market, encouraging the realization of patents, formulas and trademarks for biochemical and biotechnological and nanotechnological industries.
Since 2000 AMNOL has been able to distribute its products throughout the country and abroad under controlled temperatures and in full autonomy, monitoring stocks and distribution phases in real time, thus ensuring the traceability of the shipments.
Ahead of its time, AMNOL implemented a process for monitoring distribution and quality, which will be enforced by the Community regulations into Italy only in 2008, when AMNOL was certified in compliance with ISO 9001 for the quality management system.
Maintaining this strategy, AMNOL was once again ahead of its time: it anticipated the regulatory deadlines relating to nutritional health supplements industry and adjusted the formulas of its products for oral administration, in compliance with EU and national indications (Claims EFSA). In 2013, with the advent of new regulations regarding dermocosmetics, AMNOL provided to comply the INCI formulas of its topical products according to the specific provisions on this matter.
Twenty years later, the first important changing was followed by growth and development: in 2018 AMNOL was one of the first Italian commercial companies to obtain the prestigious certification ISO 22716 and the compliance with FDA CFR 21-part 111 for GMP (good manufacturing practices) guidelines for dermocosmetics and nutritional health supplements, which guarantee high standards of quality and safety for its manufacturing chain.
Always in 2018, AMNOL acquired the product list of a leading company and entrusted it to Euronational Srl (https://www.euronational.it/), company already 100% owned by AMNOL and well positioned on the Italian territory.
In 2019 the company extended its structure with the Marketing & Communication department, focusing on its core-business in order to supply new information tools to all the departments and end users.
In 2023, AMNOL was acquired by CERES PHARMA, a Belgian pharmaceutical company based in Ghent, which is a part of the French group NAXICAP. Both parties have come to this agreement since it fits perfectly within their strategy.
“We are pleased to be part of a strong, dynamic and fast growing international group, such as Ceres Pharma. Together, we will be stronger to execute our ambitious growth plan in Italy and we will be able to sell our products in Belgium and other Central and Eastern European countries", says Giorgio Stefanelli, CEO of Amnol group.
This collaboration will enable AMNOL to leverage CERES PHARMA's international presence to expand its business and at the same time, CERES PHARMA will benefit from AMNOL's experience and resources to strengthen its presence in Italy.